Living With CMT2C: CMT2C is rare.
Reliable information shouldn’t be.
Living With CMT2C brings together what published experts have written about CMT2C, the TRPV4-related form of Charcot-Marie-Tooth disease, for patients, families and clinicians. In plain language, with a source for every fact.
Also called HMSN 2C or TRPV4 neuropathy, and likely the same disease as SPSMA and CDSMA [6]. Every name, explained
Who are you here as?
Three starting points into the same facts.
Patients and families
I have CMT2C, or someone I love does
Start with what it is, then take it one step at a time: symptoms, care, daily life and how to help research.
Clinicians
I’m seeing a patient with CMT2C
A one-page briefing for each specialty: what is usually checked, the known cautions and the papers behind it. Pulmonology, ENT, anesthesia, orthopedics and more.
Researchers
I work on TRPV4 or axonal CMT
A read and indexed library of 271 papers, the open questions, the cohorts and studies, and a community ready to talk to you.
Three things to know first
CMT2C is a progressive disease: it weakens the hands, feet and shoulders, and that weakness usually worsens slowly over time. Unlike most forms of CMT, it often reaches the voice box and the breathing muscles, and in severe forms respiratory complications can shorten life [6]. In mild forms lifespan is normal [6].
There is no approved treatment that changes the course of CMT2C yet. None exists for any form of CMT so far [5], so care focuses on managing symptoms with a team of specialists [6].
There is real momentum. A natural history study, which follows people with TRPV4 changes over time, is under way at Johns Hopkins [101], and more drug candidates are in clinical trials for CMT than ever before [99].
Patients move research forward. By actively participating in research and clinical trials and supporting one another, we can help drive the progress needed to halt this disease in its tracks.
Clinical trials to watch
Research for CMT2C, and for CMT as a whole, is moving. Trials that are not only for CMT2C matter too: treatments aimed at nerve problems shared by many types of CMT could help all of us.
See all trials and research- You can join now
Natural history studies
Johns Hopkins runs a study of people with TRPV4 changes, for now only in the United States and Canada [101]. INC 6601, the Inherited Neuropathy Consortium’s natural history study, is open to every type of CMT [52]. Data from studies like these help design fairer, faster trials [91].
- Built for CMT2C
ABS-0871
An oral TRPV4 blocker, now called STAR-0871 [319]. Its developer, Setara Biosciences (spun out of Actio Biosciences), plans a trial in people with CMT2C in 2027 [318].
Why it means so much to us - For many types of CMT
The wider pipeline
More drug candidates are in clinical trials for CMT than ever before [99]. One example, ignaseclant (NMD670), was tested in adults with CMT1 or CMT2 [45].
Your next step
Three places to start if you want to take part in research.
See all the ways to take partConfirm your genetic diagnosis
Trials recruit by subtype, so genetic confirmation is essential [53].
Join a study and a registry
The Johns Hopkins TRPV4 study, for now in the US and Canada [101], and INC’s natural history study [52] collect the data TRPV4 research relies on. GRIN, a registry run by the Hereditary Neuropathy Foundation, is also free and open worldwide [55]. CMTA Patients as Partners in Research gives early notice of clinical trials [54]. Where to sign up.
Ask about studies
Ask your neurologist or a CMT Center of Excellence about studies you may qualify for [53].
What you’ll find here
New to CMT2C? Start with What is CMT2C? Ready to start managing it? Try Your 90-day action plan.
About CMT2C
Treatment and trials
Everyday life
Research papers
Community
For professionals
Resources
About this site
Facts about CMT2C carry a small numbered citation to a published source. Select a number to see the source. My own experiences, and a few first-hand updates from me and from Stephanie Carmody, are shared as ours, not as evidence. Where the evidence is weak, missing or disputed, I say so.
This site brings the published experts’ words on Charcot-Marie-Tooth disease type 2C (CMT2C), the form of CMT caused by changes in the TRPV4 gene, into one fully sourced place, so they are easier to digest and to search. It was last updated in .
Urgent symptoms. If you have trouble breathing, noisy breathing or a sudden change in your voice or swallowing, seek urgent medical care.
This site gathers expert sources for education. It is not medical advice. Please read the medical disclaimer.